jupiter,,,,,noted,,,,,,,,,"I feel pretty negative about that prospect but am a bit staggered (and encouraged) by the contradictory hodge-podge of trial results that Biogen seems to be putting together to support it's bid for approval of Aducanumab."

Headlines -----"Biogen stock surges despite skepticism over Alzheimer’s drug plan."

hummmmm,,and the drug only has a moderate effect!!!!,,what ever that means,,,,possibly one might remember what they had for lunch but they cant remember where they are,,,,,,,,,,,,and that gave BllB Biogen and its' partner ESTAY Eisai a $20+ billion market cap increase,,and holding,,,,,and expected to increase,,,,,,,,,Biogen was given a higher target price by at least one analyst,,,,,,,,,,,,,presently $287 ,,,,,,,,,,target $330.